These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2737852)

  • 21. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
    Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Concentration of Ca 125 in pregnant women after spontaneous or postmenopausal gonadotrophin-induced ovulation].
    Baviera G; Purello D'Ambrosio F
    Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):55-8. PubMed ID: 2798992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
    Neunteufel W; Breitenecker G
    Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
    Hunter VJ; Weinberg JB; Haney AF; Soper JT; Lavin P; Metsch L; Knapp RC; Bast RC
    Gynecol Oncol; 1990 Feb; 36(2):161-5. PubMed ID: 2404835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer.
    Zurawski VR; Orjaseter H; Andersen A; Jellum E
    Int J Cancer; 1988 Nov; 42(5):677-80. PubMed ID: 3182103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CA-125 monitoring in the management of ovarian cancer.
    Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W
    Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer.
    Kudlacek S; Schieder K; Kölbl H; Neunteufel W; Nowotny C; Breitenecker G; Biegelmayer G; Vetterlein M; Fürlinger B; Micksche M
    Gynecol Oncol; 1989 Dec; 35(3):323-9. PubMed ID: 2480931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.
    Hurteau JA; Simon HU; Kurman C; Rubin L; Mills GB
    Am J Obstet Gynecol; 1994 Mar; 170(3):918-28. PubMed ID: 8141226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
    Menczer J; Ben-Baruch G; Moran O; Lipitz S
    Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour-associated antigen CA 125 in patients with ovarian cancer.
    Heinonen PK; Tontti K; Koivula T; Pystynen P
    Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CA 125 tumour-associated antigen: a review of the literature.
    Jacobs I; Bast RC
    Hum Reprod; 1989 Jan; 4(1):1-12. PubMed ID: 2651469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors.
    Li XG; Chen DX; Schwartz PE; Yang Z
    Gynecol Oncol; 1989 Mar; 32(3):327-30. PubMed ID: 2920953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors.
    Vinokurov VL; Dudarev AL; Jurkova LE; Lapchenkov VI; Barbanel EJ
    Eur J Gynaecol Oncol; 1992; 13(2):205-8. PubMed ID: 1587297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer.
    Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U
    Oncology; 1991; 48(1):13-7. PubMed ID: 1987493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer.
    Cruickshank DJ; Paul J; Lewis CR; McAllister EJ; Kaye SB
    Br J Cancer; 1992 Apr; 65(4):597-600. PubMed ID: 1562469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of biological markers in the diagnosis and monitoring of cystadenocarcinoma].
    Bidart JM; Bellet D
    Rev Prat; 1989 Nov; 39(26):2317-20. PubMed ID: 2595221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
    Ryuko K; Iwanari O; Kitao M; Moriwaki S
    Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.